Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

NCT06410248 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06410248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06410248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Recruiting
Start date
July 23, 2024
Completion date
August 31, 2030
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma, idh-wildtype, recurrent who grade 2 glioma, recurrent who grade 3 glioma, recurrent who grade 4 glioma